Abstract:Protein-protein interactions between SH2 domains and segments of proteins that include a post-translationally phosphorylated tyrosine residue (pY) underpin numerous signal transduction cascades that allow cells to respond to their environment. Dysregulation of the writing, erasing, and reading of these posttranslational modifications is a hallmark of human disease, notably cancer. Elucidating the precise role of the SH2 domain-containing adaptor proteins Crk and CrkL in tumor cell migration and invasion is challenging because there are no specific and potent antagonists available. Crk and CrkL SH2s interact with a region of the docking protein p130Cas containing 15 potential pY-containing tetrapeptide motifs. This chapter summarizes recent efforts toward peptide antagonists for this Crk/CrkL-p130Cas interaction. We describe our protocol for recombinant expression and purification of Crk and CrkL SH2s for functional assays and our procedure to determine the consensus binding motif from the p130Cas sequence. To develop a more potent antagonist, we employ methods often associated with structure-based drug design. Computational docking using Rosetta FlexPepDock, which accounts for peptides having a greater number of conformational degrees of freedom than small organic molecules that typically constitute libraries, provides quantitative docking metrics to prioritize candidate peptides for experimental testing. A battery of biophysical assays, including fluorescence polarization, differential scanning fluorimetry and saturation transfer difference nuclear magnetic resonance spectroscopy, were employed to assess the candidates. In parallel, GST pulldown competition assays characterized protein-protein binding in vitro. Taken together, our methodology yields peptide antagonists of the Crk/CrkL-p130Cas axis that will be used to validate targets, assess druggability, foster in vitro assay development, and potentially serve as lead compounds for therapeutic intervention.

Michael Addition of Dehydroalanine-Containing MAPK Peptides to Catalytic Lysine Inhibits the Activity of Phosphothreonine Lyase

Structural Insights into the Enzymatic Mechanism of the Pathogenic MAPK Phosphothreonine Lyase.

Structural basis for the catalytic mechanism of phosphothreonine lyase

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Site-Selective Phosphoglycerate Mutase 1 Acetylation by a Small Molecule

Kinase Inhibition via Small Molecule‐Induced Intramolecular Protein Cross‐Linking

Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation

Small Molecule-Induced Post-Translational Acetylation of Catalytic Lysine of Kinases in Mammalian Cells

Mitogen-Activated Protein Kinase Phosphatase-1: A Critical Phosphatase Manipulating Mitogen-Activated Protein Kinase Signaling In Cardiovascular Disease

Phosphonylation and Activity Loss Mechanism of the Catalytic Triad of Fatty Acid Amide Hydrolase: Theoretical Study of A Model System

Acetylation of Mitogen-Activated Protein Kinase Phosphatase-1 Inhibits Toll-like Receptor Signaling

Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development

Active-Site Dynamics Of The Spvc Virulence Factor From Salmonella Typhimurium And Density Functional Model For The Catalytic Mechanism Of The Phosphthreonine Lyase

Dynamic and structural insights into allosteric regulation on MKP5 a dual-specificity phosphatase

Assaying kinase activity of the TPL-2/NF-κB1 p105/ABIN-2 complex using an optimal peptide substrate.

Dual-Action Kinase Inhibitors Control p38α MAP Kinase Threonine Dephosphorylation

Identification of peptides interfering with the LRRK2/PP1 interaction

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

Controlling Kinase Activities by Selective Inhibition of Peptide Substrates

The mechanism of covalent inhibition of LAR phosphatase by illudalic acid

Structural insight into the mechanism of Staphylococcus aureus Stp1 phosphatase.